Genscript Biotech (HK:1548) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Genscript Biotech Corporation has exercised its conversion rights to convert $70 million in convertible bonds into 106 million ordinary shares of its subsidiary, Probio Cayman. This move increases Genscript’s ownership in Probio Cayman to approximately 71.72%, enhancing its influence in the subsidiary. Investors are advised to be cautious as they evaluate the implications of this strategic financial decision.
For further insights into HK:1548 stock, check out TipRanks’ Stock Analysis page.